nei THIS MONTH IN
PSYCHOPHARMACOLOGY
Longitudinal Changes in Cognition in Individuals With Ultra-High Risk for Psychosis
September 20, 2018   

Cognitive deficits are a core feature of schizophrenia and may be present even before the onset of psychosis. In this 2-year study, researchers investigated baseline measures of cognitive functioning as well as changes in...
 Continue reading (Members only)
US Trends in Pediatric ADHD Diagnosis
September 17, 2018   

In this large epidemiological survey involving data from 186,457 children and adolescents (age 4-17 years) in the United States, the authors found that the prevalence of attention deficit-hyperactivity disorder has...
 Continue reading (Members only)
FDA Rejects NDA for ADHD Medication "Dasotraline"
September 14, 2018   

In disappointing news, the FDA has decided not to approve Sunovion's dasotraline, a dual dopamine and norepinephrine reuptake inhibitor, for the treatment of attention deficit-hyperactivity disorder (ADHD)....
 Continue reading (Members only)
Ketamine's Antidepressant Mechanism Linked to the Opioid System?
September 10, 2018   

Ketamine has drawn excitement in recent years as a fast-acting and effective treatment for severe depression, improving symptoms within just hours. However, exactly how ketamine works to treat depression is not known...
 Continue reading
Attention-Training Video Game May Rewire Brain in ADHD
September 6, 2018   

A brain-computer interface (BCI) attention training game system has shown promise for treating attention deficit/hyperactivity disorder (ADHD) children with inattentive symptoms...
 Continue reading (Members only)
Study Finds that the Only Safe Amount of Alcohol is None
September 1, 2018   

A recent global study, conducted by 512 researchers from 243 institutions, showed that the level of alcohol consumption that minimized harmful health consequences was zero...
 Continue reading (Members only)
MDMA for the Treatment of PTSD
August 27, 2018   

Although still investigational, the psychogenic compound 3,4-methylenedioxymethamphetamine (MDMA) -administered in conjunction with psychotherapy- has shown long-lasting benefit to patients suffering with PTSD....
 Continue reading (Members only)
Evening-Dosed Stimulant Approved for ADHD
August 24, 2018   

The US Food and Drug Administration (FDA) has approved a novel extended-release formulation of methylphenidate for the treatment of ADHD in patients age 6 and up...
 Continue reading (Members only)
Metabolic Effects of Antipsychotics in Children
August 20, 2018   

Recent years have brought much concern over the effects of antipsychotics on metabolic parameters in the youth population, especially since antipsychotics are often used off-label to treat a wide variety of issues (e.g., disruptive behavioral disorder) in children and adolescents....
 Continue reading (Members only)
Meta-Analysis: Comparative Efficacy and Safety of ADHD Medication
August 17, 2018   

A recent meta-analysis compared the efficacy and tolerability of oral medications for attention deficit hyperactivity disorder...
 Continue reading (Members only)
12345678910...
Top of Page